These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 14617769)

  • 1. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
    Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
    Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
    Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
    Meunier JC; Engle RE; Faulk K; Zhao M; Bartosch B; Alter H; Emerson SU; Cosset FL; Purcell RH; Bukh J
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4560-5. PubMed ID: 15767578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
    Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
    Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
    Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
    Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
    Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
    Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
    Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
    Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies.
    Duan H; Struble E; Zhong L; Mihalik K; Major M; Zhang P; Feinstone S; Feigelstock D
    Vaccine; 2010 Jun; 28(25):4138-44. PubMed ID: 20433800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predominance of antibodies to hepatitis C virus envelope proteins in various disease statuses of hepatitis C.
    PodurI CD; Khanna A; Khundmiri SJ; Khaja MN; Kumar KS; Sugunan VS; Habibullah CM; Das MR
    Acta Virol; 2001 Feb; 45(1):1-6. PubMed ID: 11394572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
    Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
    Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity.
    Schofield DJ; Bartosch B; Shimizu YK; Allander T; Alter HJ; Emerson SU; Cosset FL; Purcell RH
    Hepatology; 2005 Nov; 42(5):1055-62. PubMed ID: 16250048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.
    Zibert A; Schreier E; Roggendorf M
    Virology; 1995 Apr; 208(2):653-61. PubMed ID: 7538251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.
    Johansson DX; Voisset C; Tarr AW; Aung M; Ball JK; Dubuisson J; Persson MA
    Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16269-74. PubMed ID: 17911260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library.
    Mink MA; Benichou S; Madaule P; Tiollais P; Prince AM; Inchauspe G
    Virology; 1994 Apr; 200(1):246-55. PubMed ID: 7510436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence.
    Watanabe K; Yoshioka K; Ito H; Ishigami M; Takagi K; Utsunomiya S; Kobayashi M; Kishimoto H; Yano M; Kakumu S
    Virology; 1999 Nov; 264(1):153-8. PubMed ID: 10544140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.